ESSA Common Stock vs Other Current Liab Analysis
EPIX Stock | USD 6.39 0.09 1.43% |
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Common Stock and its Other Current Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.
Common Stock vs Other Current Liab
Common Stock vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Common Stock account and Other Current Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between ESSA Pharma's Common Stock and Other Current Liab is 0.41. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Common Stock and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of ESSA Pharma are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock i.e., ESSA Pharma's Common Stock and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.41 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Common Stock
Other Current Liab
Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Enterprise Value is likely to rise to about 97 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2024.
ESSA Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Other Current Liab | 676.0 | 2.4M | 1.2M | 1.4M | 1.6M | 1.0M | |
Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 4.0M | 3.3M | |
Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 175.8M | |
Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (161.5M) | (153.4M) | |
Accounts Payable | 1.1M | 1.4M | 954.6K | 2.0M | 2.3M | 1.6M | |
Cash | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 37.2M | |
Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 132.7M | 139.3M | |
Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 121.6K | 115.5K | |
Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
Other Current Assets | 24.3M | 2.2M | 1.8M | 585.4K | 673.2K | 639.6K | |
Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 56.4M | 59.2M | |
Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 3.1M | 3.6M | |
Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 171.1M | 179.7M | |
Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 92.4K | 87.8K | |
Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (30.3M) | (31.8M) | |
Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 292.7K | 301.5K | |
Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 170.3M | 178.8M | |
Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 50.7M | 53.2M | |
Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 295.8K | 201.5K | |
Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 72.3K | 68.7K | |
Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 103.4M | |
Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 167.1M | 101.6M | |
Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 198.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ESSA Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ESSA Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Essa Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Essa Pharma Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.14) | Return On Equity (0.19) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.